{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '7.2.1.5. Reporting and Follow-up Requirements for Pregnancies', '7.2.1.5.1. Pregnancies in Female Patients', 'Serum pregnancy tests will be performed centrally at Screening. Urine pregnancy tests will', 'be conducted and analyzed locally before randomization and thereafter at visits as detailed in', 'the general SoA (Table 1).', 'If a patient becomes pregnant after the administration of IMP and up to 90 days after the', \"patient received the last infusion, the Sponsor and/or Sponsor's designee should be informed\", \"immediately (i.e., within 24 hours of the trial site's knowledge of the event). The following\", 'actions will be performed:', 'The patient should immediately be discontinued from randomized treatment.', 'The patient should have EoT assessments.', 'All assessments for EoT (see Sections 4.4.2 and 5.6) must be performed unless', 'contraindicated by pregnancy (harmful to fetus) or unless the patient withdraws', 'informed consent.', 'The Investigator must update the patient with information currently known about potential', 'risks and about available treatment alternatives. The pregnancy should be followed-up to', 'determine outcome, including spontaneous or voluntary termination, details of the birth, and', 'the presence or absence of any birth defects, congenital abnormalities, or maternal and/or', 'newborn complications.', 'If required by local regulations, the female participant will be requested to sign a separate', 'pregnancy ICF.', 'Full details will be recorded on a paper Pregnancy Report Form and submitted via email or', 'fax (see the Safety Mailbox/Fax details on the title page of this protocol), and reporting', 'details will be specified in the trial manual. The Investigator will update the Pregnancy', 'Report Form with additional information as soon as the outcome of the pregnancy is known.', 'If the outcome of the pregnancy is an SAE, then this must be additionally reported as an SAE', 'on the appropriate SAE Report Form.', '7.2.1.5.2. Pregnancies in Female Partners of Male Patients', 'Male patients will be instructed through the ICF to immediately inform the Investigator if', 'their partner becomes pregnant during the trial or up to 90 days after they received the last', 'infusion of IMP. A Pregnancy Report Form should be completed by the Investigator within', '24 hours after learning of the pregnancy and submitted via email or fax (see the Safety', 'Mailbox/Fax details on the title page of this protocol). Attempts should be made to collect', 'argenx BVBA', 'Confidential', 'Page 83 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'and report details of the course and outcome of any pregnancy in the partner of a male patient', 'exposed to the IMP.', 'The pregnant partner will need to sign an ICF to allow for follow-up on her pregnancy. Once', 'the ICF has been signed, the Investigator will update the Pregnancy Report Form with', 'additional information on the course and outcome of the pregnancy. An Investigator, who is', 'contacted by the male patient or his pregnant partner, may provide information on the risks of', 'the pregnancy and the possible effects on the fetus, to support an informed decision in', 'cooperation with the treating physician and/or obstetrician.', '7.2.2.', 'Clinical Laboratory Evaluations', 'Blood and urine samples for determination of clinical chemistry, hematology, urinalysis, PK,', 'PD, viral testing, and ADA will be analyzed at a central lab as indicated in the general SoA', '(Table 1) and Appendix 6. Patients need to be fasting for at least 8 hours prior to the', 'sampling for clinical laboratory tests as from Screening up to EoS. Retesting is allowed once', \"after Sponsor's written approval (see Section 4.7).\", 'Additional safety samples may be collected if clinically indicated at the discretion of the', 'Investigator.', 'For all patients of childbearing potential, a serum pregnancy test will be performed centrally', 'at Screening (on the samples taken for clinical laboratory tests), and a urine pregnancy test', 'will be conducted and analyzed locally at the site (on the urine samples taken for urinalysis)', 'at all visits, except at Screening.', 'The estimated total maximum blood volume needed for a patient during the trial (when', 'completing the trial up until the last visit) is between 225 mL for a patient who receives', '1 Treatment Cycle only and 385 mL for a patient who receives the maximum of 3 treatment', 'cycles.', 'Clinical laboratory tests will be reviewed for results of potential clinical significance at all', 'time points throughout the trial. The Investigator will evaluate any change in laboratory', 'values. If the Investigator determines a laboratory abnormality to be clinically significant, it', 'will be considered as a laboratory AE; however, if the abnormal laboratory value is', 'consistent with a current diagnosis, it may be documented accordingly without being', 'reported as an AE.', 'The details of sampling, handling, storage, and transportation of the samples will be', 'described in the laboratory manual. The actual sample collection date and time must be', \"entered in the patient's source documents and on the central lab assessment eCRF page.\", 'Besides the urine pregnancy test which will be conducted and analyzed locally, all samples', 'will be analyzed centrally.', 'CCI', 'argenx BVBA', 'Confidential', 'Page 84 of 110']\n\n###\n\n", "completion": "END"}